Johnson & Johnson (NYSE:JNJ) Shares Up 1.3% – Here’s What Happened

Johnson & Johnson (NYSE:JNJ)’s share price was up 1.3% on Friday . The stock traded as high as $235.50 and last traded at $234.6730. Approximately 5,460,502 shares traded hands during mid-day trading, a decline of 35% from the average daily volume of 8,408,575 shares. The stock had previously closed at $231.73.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J received approval in China for nipocalimab, a key pipeline win that expands the drug’s commercial potential and adds to the company’s growth outlook. Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: Analysts highlighted J&J’s diversified pharma and MedTech businesses, pipeline progress, and stronger 2026 outlook as reasons it appears better positioned than Pfizer amid patent risk concerns. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
• Positive Sentiment: The company unveiled its Shockwave C2 Aero Coronary IVL Catheter, supporting its MedTech growth story in the large coronary artery disease market. Johnson & Johnson (JNJ) Unveils Next‑Gen Catheter for Coronary Artery Disease
• Positive Sentiment: J&J also announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s Department of Health, which could strengthen its surgery and digital-health positioning over time. Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health – Abu Dhabi
• Neutral Sentiment: Recent articles on J&J’s defensive-growth profile and dividend appeal reinforce its image as a reliable blue chip, but they are not major new catalysts for the stock. Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Negative Sentiment: ImmunityBio’s presentation on ANKTIVA versus J&J’s TAR-200 introduces competitive pressure in bladder cancer, though the news is still early and may not materially change J&J’s near-term fundamentals. IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J’s TAR-200

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on JNJ shares. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Daiwa Securities Group lifted their target price on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research report on Thursday, April 16th. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Guggenheim boosted their price objective on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Finally, Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Price Performance

The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $564.91 billion, a P/E ratio of 27.13, a P/E/G ratio of 2.25 and a beta of 0.27. The company’s 50-day simple moving average is $234.19 and its 200 day simple moving average is $223.20.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson’s payout ratio is currently 61.97%.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. Auto Owners Insurance Co lifted its holdings in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $6,924,523,000. Capital World Investors bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $2,005,942,000. Diamant Asset Management Inc. increased its position in shares of Johnson & Johnson by 24,436.5% during the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after purchasing an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after purchasing an additional 3,731,074 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.